- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05649748
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Insmed Medical Information
- Phone Number: 1-844-446-7633
- Email: medicalinformation@insmed.com
Study Locations
-
-
-
Córdoba, Argentina, X5000DCE
- Recruiting
- ARG004
-
Córdoba, Argentina, X5000FPQ
- Recruiting
- ARG001
-
-
Buenos Aires
-
Quilmes, Buenos Aires, Argentina, B1878GEG
- Recruiting
- ARG009
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, S2013KDS
- Recruiting
- ARG006
-
-
Tucuman
-
San Miguel de Tucuman, Tucuman, Argentina, T4000AXL
- Recruiting
- ARG007
-
-
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30430-142
- Recruiting
- BRA004
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-003
- Recruiting
- BRA006
-
-
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Germany, 69126
- Recruiting
- GER005
-
-
Schleswig-Holstein
-
Lübeck, Schleswig-Holstein, Germany, 23562
- Recruiting
- GER002
-
-
-
-
-
Monza, Italy, 20900
- Recruiting
- ITA005
-
-
Lombardia
-
Pavia, Lombardia, Italy, 27100
- Recruiting
- ITA002
-
-
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 060-8543
- Recruiting
- JPN005
-
-
Okayama
-
Okayama-Shi, Okayama, Japan, 701-1192
- Recruiting
- JPN002
-
-
Osaka
-
Suita-Shi, Osaka, Japan, 564-8565
- Recruiting
- JPN003
-
-
-
-
Kedah
-
Alor Setar, Kedah, Malaysia, 5460
- Recruiting
- MYS005
-
-
Pahang
-
Kuantan, Pahang, Malaysia, 25200
- Recruiting
- MYS002
-
-
Selangor
-
Sungai Buloh, Selangor, Malaysia, 47000
- Recruiting
- MYS004
-
-
-
-
-
San Luis Potosi, Mexico, 78250
- Recruiting
- MEX004
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64718
- Recruiting
- MEX001
-
-
-
-
-
Makati City, Philippines, 1229
- Recruiting
- PHL002
-
-
-
-
-
Belgrade, Serbia, 11000
- Recruiting
- SRB003
-
-
-
-
-
Santander, Spain, 39008
- Recruiting
- ESP001
-
Sevilla, Spain, 41009
- Recruiting
- ESP003
-
-
-
-
Avon
-
Bath, Avon, United Kingdom, BA1 3NG
- Recruiting
- GBR001
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- USA006
-
Chicago, Illinois, United States, 60612
- Recruiting
- USA001
-
-
New York
-
New York, New York, United States, 10021
- Recruiting
- USA102
-
-
Texas
-
Dallas, Texas, United States, 75246
- Recruiting
- USA016
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female participants who completed end of treatment study visit in Study INS1009-201, INS1009-202, or any other lead-in PAH TPIP study. Participants for whom the OLE study was not available at the time of their completion of the lead-in study are eligible for enrolment within one year of their lead-in end of treatment visit.
- Complete baseline screening assessments to confirm eligibility to participate if more than 30 days have elapsed since the end of the study visit in Study INS1009-201, INS1009-202, or any other lead-in PAH TPIP study.
Exclusion Criteria:
- Initiation of parenteral administration of prostacyclin analogues (eg, TRE, epoprostenol) since the completion of studies INS1009-201, INS1009-202 or other TPIP studies. Initiation of inhaled prostacyclin analogues (eg, TRE [Tyvaso] or iloprost) and oral prostacyclin analogues (eg, TRE [Orenitram]) or receptor agonists (eg, selexipag) are permitted if stopped 24 hours prior to the start of study drug administration.
- Any new ventricular or supraventricular tachyarrhythmia except for paroxysmal atrial fibrillation and any new symptomatic bradycardia.
- New-onset of heart disease including left ventricular ejection fraction (LVEF) ≤40% or clinically significant valvular, constrictive, or symptomatic atherosclerotic heart disease (eg, stable angina, myocardial infarction, etc).
- New evidence of thromboembolic disease as assessed by ventilation/perfusion (VQ) scan, pulmonary angiography, or pulmonary computed tomography (CT) scan.
- Active and current symptomatic coronavirus disease 2019 (COVID-19) or previous severe disease and/or hospitalization due to COVID-19.
- Interval organ transplantation.
- New active liver disease or hepatic dysfunction.
- Interval malignancy with exception of completely treated in situ carcinoma of the cervix and completely treated non-metastatic squamous or basal cell carcinoma of the skin.
- Use of any investigational drug/device or participation in any investigational study within 30 days prior to screening, not including TPIP of the lead-in study.
- Current use of cigarettes (as defined by Centers for Disease Control and Prevention [CDC]) or e-cigarettes: An adult who has smoked at least 100 cigarettes in his or her lifetime, who smokes either every day or some days.
- Participants who currently inhale marijuana (recreational or medical).
Note: Other inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treprostinil Palmitil Inhalation Powder (TPIP)
Participants who are not transitioning immediately from other TPIP studies:INS1009-201(NCT04791514), INS1009-202(NCT05147805) and other lead-in studies, will be given TPIP, once daily (QD), starting with 80 micrograms (μg), up-titrated to highest tolerated dose between 80 μg and 640 μg during 3-week titration period that maybe increased upto maximum dose of 1280 μg QD post initial titration, per investigator's assessment. Overall treatment period=24 months. Participants transitioning immediately from randomized blinded lead-in TPIP study and who previously received:
|
Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
Other Names:
Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by Severity
Time Frame: From screening up to last follow up visit (Up to approximately 26 months)
|
From screening up to last follow up visit (Up to approximately 26 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative Change From Pre-OLE Baseline in 6MWD
Time Frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
|
Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
|
|
Change From Pre-OLE Baseline in the Concentration of N-Terminal Fragment B-Type Natriuretic Peptide (NT-proBNP) in Blood
Time Frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
|
Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
|
|
Change From Pre-OLE Baseline in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Score
Time Frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
|
Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
|
|
Change From Pre-OLE Baseline in New York Heart Association/ World Health Organization (NYHA/WHO) Functional Capacity Class
Time Frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
|
Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
|
|
Plasma Concentration Levels of Treprostinil Palmitil (TP) and Treprostinil (TRE)
Time Frame: OLE Baseline (Day 1), Months 6, 12, 18, and 24
|
OLE Baseline (Day 1), Months 6, 12, 18, and 24
|
|
Absolute Change From Pre-Open Label Extension (OLE) Baseline in 6-Minute Walk Distance (6MWD)
Time Frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
|
Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
|
|
Annualized Clinical Worsening Event Rate
Time Frame: OLE Baseline (Day 1) up to Month 24 or early discontinuation
|
Annualized clinical worsening event rate is defined as the total number of clinical worsening events that occurred during the treatment period divided by the total number of participant-years during the treatment period.
Clinical worsening events are one of the following: All-cause death, or onset of TEAE with a fatal outcome occurring ≤ 14 days after study drug discontinuation; Hospitalization for right heart failure (for > 48 hours), heart-lung or lung transplant, or atrial septostomy; Addition (or increase in dose) of specified PAH-specific medications; Combined occurrence of events including ≥20% decrease in 6MWD, worsening WHO/NYHA functional capacity class, and appearance of or worsening of signs/symptoms of right heart failure from baseline.
|
OLE Baseline (Day 1) up to Month 24 or early discontinuation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- INS1009-203
- 2022-001951-18 (EudraCT Number)
- 2023-505539-11-00 (Other Identifier: EU CT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Treprostinil Palmitil
-
Insmed IncorporatedCompletedPulmonary HypertensionBelgium, Germany, Spain, Argentina, Australia, Italy, United Kingdom
-
Insmed IncorporatedTerminatedPulmonary Arterial HypertensionUnited States
-
Insmed IncorporatedRecruitingPulmonary Arterial HypertensionUnited States, Spain, Argentina, Australia, Belgium, Brazil, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Switzerland, United Kingdom, Serbia, Austria, Denmark
-
Insmed IncorporatedRecruitingPulmonary Hypertension | Interstitial Lung DiseaseBelgium, Germany, Spain, Italy, Argentina, Australia, United Kingdom
-
Insmed IncorporatedCompleted
-
United TherapeuticsTerminatedPulmonary Hypertension Associated With HFpEFUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States, Canada, India, United Kingdom, Spain, Israel, Australia, Belgium, France, Austria, China, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Sweden
-
United TherapeuticsTerminatedPulmonary Hypertension | Heart Failure With Preserved Ejection FractionUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States
-
United TherapeuticsActive, not recruitingPulmonary Arterial HypertensionUnited States